• CRO M&A Market in 2020 (So Far)

    There haven’t been many deals targeting contract research organizations (CRO) in 2020, especially compared to previous years, which makes sense. Life science companies are all slowing down clinical trials (COVID-19 vaccine research excluded) to adhere to social distancing guidelines, meaning CRO services are just not in as high demand. For... Read More »
  • Ophthalmology Groups Are Still Selling

    Despite the effects of COVID-19 on physician groups, investors are still acquiring ophthalmology groups, especially in the third quarter, according to DSO. Just last week, EyeSouth Partners acquired Retina Associates of Middle Georgia (RAMG) for an undisclosed sum. Based in Macon, Georgia, RAMG provides treatment for the retina, macula, and... Read More »
  • Hospice M&A Activity Surges in 2020

    Despite the volatile market conditions for healthcare M&A, hospice targets have remained a remarkably consistent draw for investors, according to data captured in DSO. In the second quarter of 2020, 70% of HH&H transactions were for hospice specific targets, or targets that provided only hospice services, instead of a mix of hospice and... Read More »
  • Teladoc Health and Livongo Health Merge

    The virtual care giant Teladoc Health, Inc. (NYSE: TDOC) is having a wild year. The company’s second-quarter earnings reports showed Teladoc’s year-over-year revenues surged by 85% to $241 million, and its total telehealth visits rose to 2.8 million, a year-over-year increase of 203%, all thanks to the effects of COVD-19. And now,... Read More »
  • Health Care M&A Deals, August 7, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was... Read More »

Generic Drug Deals Are Getting Rarer

The patent cliff is boosting the volume and market share of generic pharmaceutical products. Generics account for 88% of all prescriptions filled annually in the United States, according to the latest IMS Report. For good reason, since generic drugs typically cost between 50% to 70% less than their branded equivalents. Governments and managed care companies have historically been proponents of generic drugs, which can lower the cost of healthcare across the entire continuum. 2015 was the year of the M&A boom in the generic drug segment, with 25 deals totaling $64.8 billion. The targets include the companies focused on generic pharmaceuticals as well as the rights to generic... Read More »

Mylan Adds Topical Pharmaceuticals Business

Mylan NV (NASDAQ: MYL) still has money to spend, following its $9.9 billion deal for Swedish drug maker Meda AB in February. On Friday, May 13, RoundTable Healthcare Partners announced that its portfolio company, Renaissance Acquisition Holdings, LLC, had agreed to sell its non-sterile topical drug business to Mylan for $950 million, plus additional contingent payments of up to $50 million. The topical division is a specialty pharmaceutical business focused on manufacturing, developing, sales and marketing of branded and generic drug products. The acquisition brings a complementary portfolio of approximately 25 branded and generic topical products, an active pipeline of approximately 25... Read More »

Mylan Bags Meda AB on the Second Try

The pharmaceutical M&A sector has gotten very quiet in February, with just five deals announced as of Feb. 17. Compared with the 11 announced in January 2016 and 13 announced in February 2015, deal making has definitely slowed down. So it was good news to hear that Mylan NV (NASDAQ: MYL) agreed to pay $9.9 billion, including debt, to acquire Swedish generic drug maker Meda AB (STO: MEDA). Back in 2014, when Mylan was still based in the United States and known as Mylan, Inc., it made an unsuccessful run at Meda. Of course, late last year it carried on an all-out hostile takeover battle for Perrigo Company (NYSE: PRGO) that proved unsuccessful in the end. This time around, the Meda... Read More »